कृपया अन्य खोज का प्रयास करें
VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company’s drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Renu Virmani | - | - | Member of Advisory Board |
Jean-Lucien Rouleau | - | - | Member of Clinical Advisory Board |
Donald H. Maurice | - | - | Scientific Advisor |
Garret A. FitzGerald | - | - | Scientific Advisor |
Frederick B. Craves | 76 | 2007 | Director |
Marcelo Di Carli | - | - | Member of Clinical Advisory Board |
Peter Libby | 75 | - | Member of Clinical Advisory Board |
Tod Klingler | 58 | - | Scientific Advisor |
Thomas Quertermous | 70 | 2004 | Chief Scientific Officer & Member of Scientific Advisory Board |
John R. Larson | - | 2003 | Director |
Paul M. Ridker | - | - | Member of Advisory Board |
Christopher Glass | - | - | Scientific Advisor |
David T. Howard | 72 | 2007 | Independent Director |
Marco Conti | - | - | Scientific Advisor |
Robert R. Fenichel | - | - | Member of Clinical Advisory Board |
Israel F. Charo | 72 | - | Scientific Advisor |
Colin Funk | - | - | Scientific Advisor |
Jean Claude Tardif | - | - | Member of Clinical Advisory Board |
Marc Pfeffer | - | - | Chair of Clinical Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है